Literature DB >> 22072165

Outcomes of patients with untreated severe aortic stenosis in real-world practice.

Suresh Perera1, Namal Wijesinghe, Elene Ly, Gerard Devlin, Sanjeevan Pasupati.   

Abstract

BACKGROUND: Surgical aortic valve replacement remains the gold standard of the treatment of severe symptomatic aortic stenosis but is often not considered due to excessive risk factors and comorbidities especially in elderly patients. We describe the burden of untreated severe aortic stenosis at a tertiary care hospital in New Zealand.
METHOD: Consecutive patients with severe aortic stenosis presented between January-December, 2005 were studied retrospectively. Outcome assessment included mortality, hospital stay and on going symptoms (angina >CCS class II, dyspnoea >NYHA class II and syncope).
RESULTS: A total of 105 patients with severe aortic stenosis were identified (mean age 76 plus or minus 13 years, 51% men). Patients were divided into 3 groups according to the management strategy. (Group 1: Not referred for surgery as asymptomatic (n=25), Group 2: Declined for surgery (n=41), Group 3: Accepted for surgery (n=39)). Median follow-up was 34 months (interquartile range: 16-36 months). All-cause mortality in Group 1, Group 2 and Group 3 were 36%, 73% and 18% respectively while hospital days per 100 patient-years were 3.5, 10.1 and 6.4 and symptoms on last follow-up were 0%, 64% and 0% respectively. Almost half of symptomatic patients (Group 2 versus 3) were denied valve surgery due to comorbidities. Symptomatic patients had a significant mortality (p<0.0001) benefit with less hospitalisations (p<0.0001) post surgery.
CONCLUSIONS: Untreated symptomatic severe aortic stenosis is associated with a poor prognosis and significant morbidity. For symptomatic patients with severe aortic stenosis who are denied surgery, alternative therapies such as transcatheter aortic valve implantation could be a viable option.

Entities:  

Mesh:

Year:  2011        PMID: 22072165

Source DB:  PubMed          Journal:  N Z Med J        ISSN: 0028-8446


  7 in total

1.  Interstitial lung abnormality is prevalent and associated with worse outcome in patients undergoing transcatheter aortic valve replacement.

Authors:  Michael Kadoch; Aleksandar Kitich; Shehabaldin Alqalyoobi; Elyse Lafond; Elena Foster; Maya Juarez; Cesar Mendez; Thomas W Smith; Garrett Wong; Walter D Boyd; Jeffrey Southard; Justin M Oldham
Journal:  Respir Med       Date:  2018-02-27       Impact factor: 3.415

2.  Reproducible In Vitro Tissue Culture Model to Study Basic Mechanisms of Calcific Aortic Valve Disease: Comparative Analysis to Valvular Interstitials Cells.

Authors:  Andreas Weber; Melissa Pfaff; Friederike Schöttler; Vera Schmidt; Artur Lichtenberg; Payam Akhyari
Journal:  Biomedicines       Date:  2021-04-26

Review 3.  Cell Sources for Tissue Engineering Strategies to Treat Calcific Valve Disease.

Authors:  Eva Jover; Marco Fagnano; Gianni Angelini; Paolo Madeddu
Journal:  Front Cardiovasc Med       Date:  2018-11-06

4.  Patient-centered benefit-risk analysis of transcatheter aortic valve replacement.

Authors:  Kevin Marsh; Natalia Hawken; Ella Brookes; Carrie Kuehn; Barry Liden
Journal:  F1000Res       Date:  2019-04-08

5.  One-Year Costs Associated with Hospitalizations Due to Aortic Stenosis in Canada.

Authors:  Jean-Eric Tarride; Sandra Lauck; Madhu K Natarajan; Anita W Asgar; Trinh Luong; Gord Blackhouse
Journal:  CJC Open       Date:  2020-09-19

6.  Artificial Intelligence Models Reveal Sex-Specific Gene Expression in Aortic Valve Calcification.

Authors:  Philip Sarajlic; Oscar Plunde; Anders Franco-Cereceda; Magnus Bäck
Journal:  JACC Basic Transl Sci       Date:  2021-04-14

7.  Patient values and preferences on transcatheter or surgical aortic valve replacement therapy for aortic stenosis: a systematic review.

Authors:  Lyubov Lytvyn; Gordon H Guyatt; Veena Manja; Reed A Siemieniuk; Yuan Zhang; Thomas Agoritsas; Per O Vandvik
Journal:  BMJ Open       Date:  2016-09-29       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.